Literature DB >> 17357098

Immune based therapies in cancer.

C Krüger1, T F Greten, F Korangy.   

Abstract

Immunotherapy of cancer has become a more promising approach in the past decade. Developments in both basic immunology and tumor biology have increased our knowledge of the interactions between the tumor cells and the immune system. The molecular identification of tumor-associated antigens and understanding of immunological pathways have cleared the way for development of different strategies for anti-tumor vaccines. The success of any cancer vaccine relies on the induction of an effective tumor-specific immune response to break tolerance and to elicit a long lasting anti-tumor immunity. It is also increasingly clear that the interactions of host-tumor are quite complicated leading to tumor escape mechanisms, which add another level of difficulty to this interaction. This review will summarize the recent developments in tumor immunotherapy as well as the clinical trials addressing novel immunotherapeutic approaches to cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17357098     DOI: 10.14670/HH-22.687

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  6 in total

1.  Training the Defense System for Modern-Day Warfare: The Horizons for Immunotherapy and Vaccines for Cancer.

Authors:  Narendra Kumar; Jayshree Mishra; Sohel H Quazi
Journal:  J immunodefic Disord       Date:  2012-07-21

2.  Cancer vaccination drives Nanog-dependent evolution of tumor cells toward an immune-resistant and stem-like phenotype.

Authors:  Kyung Hee Noh; Young-Ho Lee; Ju-Hong Jeon; Tae Heung Kang; Chih-Ping Mao; T-C Wu; Tae Woo Kim
Journal:  Cancer Res       Date:  2012-02-14       Impact factor: 12.701

Review 3.  Prospective of colon cancer treatments and scope for combinatorial approach to enhanced cancer cell apoptosis.

Authors:  Jayshree Mishra; Joseph Drummond; Sohel H Quazi; Satya Sridhar Karanki; J J Shaw; Ben Chen; Narendra Kumar
Journal:  Crit Rev Oncol Hematol       Date:  2012-10-23       Impact factor: 6.312

4.  Mesothelin-specific cell-based vaccine generates antigen-specific immunity and potent antitumor effects by combining with IL-12 immunomodulator.

Authors:  M-C Chang; Y-L Chen; Y-C Chiang; T-C Chen; Y-C Tang; C-A Chen; W-Z Sun; W-F Cheng
Journal:  Gene Ther       Date:  2015-08-11       Impact factor: 5.250

Review 5.  Immunotherapy for cancer: synthetic carbohydrate-based vaccines.

Authors:  Therese Buskas; Pamela Thompson; Geert-Jan Boons
Journal:  Chem Commun (Camb)       Date:  2009-07-22       Impact factor: 6.222

6.  Oncolytic adenovirus coexpressing interleukin-12 and decorin overcomes Treg-mediated immunosuppression inducing potent antitumor effects in a weakly immunogenic tumor model.

Authors:  Eonju Oh; Il-Kyu Choi; JinWoo Hong; Chae-Ok Yun
Journal:  Oncotarget       Date:  2017-01-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.